Advanced Respiratory Nursing — GCC Clinical Guide

🫁Breathing Pattern Assessment

Parameter	Normal	Abnormal Findings
Rate (RR)	12–20 /min	<12 bradypnoea; >20 tachypnoea; >30 severe distress
Rhythm	Regular	Cheyne-Stokes (ICSOL/HF); Biot's (brainstem injury); Kussmaul (metabolic acidosis)
Depth	Adequate tidal volume	Shallow (splinting/pain); deep (DKA/hyperventilation)
Effort	Effortless	Nasal flare, pursed-lip breathing, tripod positioning, use of accessory muscles

Accessory Muscle Use

Sternocleidomastoid: Indicates severe inspiratory effort
Scalene muscles: Active even at rest in severe disease
Intercostal recession: Suprasternal, supraclavicular, intercostal
Abdominal muscles: Active expiration — COPD/severe obstruction

Paradoxical Breathing: Abdomen moves IN during inspiration (normally OUT). Indicates diaphragmatic fatigue or paralysis — impending respiratory arrest.

⚠️Respiratory Failure Classification

Type 1 — Hypoxaemic
PaO2 < 8 kPa (60 mmHg)
PaCO2 normal or low
Causes: pneumonia, ARDS, PE, pulmonary oedema

Type 2 — Hypercapnic
PaCO2 > 6 kPa (45 mmHg)
+ hypoxaemia usually present
Causes: COPD, OHS, neuromuscular, severe asthma

Pulse Oximetry Limitations

Anaemia: SpO2 may read falsely normal; tissue O2 delivery still poor
Nail varnish/acrylic nails: Can cause falsely low readings — remove or use finger side
Poor peripheral perfusion: Vasoconstriction, hypotension, Raynaud's — use ear probe or forehead
Carbon monoxide poisoning: SpO2 reads near 100% (CO-Hb and Oxy-Hb absorb same wavelength) — requires co-oximetry ABG
Methaemoglobinaemia: SpO2 drifts towards 85% regardless of true value
Dark skin pigmentation: Evidence of SpO2 overestimation (up to 3%) — consider lower threshold for intervention

🔬ABG Systematic Interpretation

5-Step Approach

pH: Normal 7.35–7.45. <7.35 = acidosis; >7.45 = alkalosis
PaCO2: Normal 4.7–6.0 kPa (35–45 mmHg). ↑ respiratory acidosis; ↓ respiratory alkalosis
HCO3: Normal 22–26 mmol/L. ↓ metabolic acidosis; ↑ metabolic alkalosis
Compensation: Opposite system moves to correct pH (partial vs full)
PaO2 + oxygenation: Normal >10.6 kPa (80 mmHg) on air; calculate A-a gradient

Normal ABG Values

Parameter	kPa	mmHg / other
pH	7.35 – 7.45
PaCO2	4.7 – 6.0 kPa	35 – 45 mmHg
HCO3	22 – 26 mmol/L
PaO2 (air)	>10.6 kPa	>80 mmHg
Base excess	–2 to +2 mmol/L
SaO2	>94%

Compensation Rules

Respiratory acidosis: HCO3 ↑ by 1 per 10 mmHg CO2 ↑ (acute); 3.5 per 10 (chronic)
Metabolic acidosis: Expected PaCO2 = (1.5 × HCO3) + 8 ± 2 (Winter's formula)
Metabolic alkalosis: PaCO2 ↑ 0.7 per 1 mmol/L HCO3 ↑

💨Peak Flow Measurement

Technique (PEFR)

Patient stands (or sits upright if unable)
Set pointer to zero on peak flow meter
Patient inhales maximally — full inspiration to TLC
Seal lips tightly around mouthpiece (use nose clip if needed)
Blast out as hard and fast as possible — NOT sustained blow
Record reading; repeat 3 times; record highest value

Diurnal Variation: >20% variation between morning (lowest) and evening readings is diagnostic of asthma. Record AM (pre-bronchodilator) and PM values.

📊Spirometry Interpretation

Pattern	FEV1/FVC	FEV1	FVC	Examples
Obstructive	<0.70	↓	Normal/↓	COPD, Asthma
Restrictive	Normal (>0.70)	↓	↓↓	Fibrosis, obesity, neuromuscular
Mixed	<0.70	↓↓	↓	Advanced COPD + fibrosis

Key Points

FEV1/FVC ratio is the primary discriminator: obstructive <0.70
Bronchodilator reversibility: FEV1 ↑ >200 mL AND >12% — significant (asthma vs COPD)
Restrictive: FVC <80% predicted; confirm with lung volumes (TLC <80%)
Perform post-bronchodilator for COPD diagnosis (post-BD FEV1/FVC <0.70)

Interactive ABG Interpretation Tool

Enter arterial blood gas values to receive systematic clinical interpretation and suggested actions.

PaCO2

CO2 Unit

HCO3 (mmol/L)

PaO2

PaO2 Unit

FiO2 (%)

Interpretation Result

📈GOLD Staging (Severity by Spirometry)

GOLD Stage	Severity	FEV1 (% predicted, post-BD)
GOLD 1	Mild	≥ 80%
GOLD 2	Moderate	50 – 79%
GOLD 3	Severe	30 – 49%
GOLD 4	Very Severe	< 30%

Prerequisite: FEV1/FVC <0.70 post-bronchodilator confirms airflow obstruction. Staging alone does not guide treatment — use ABCD assessment.

🅰🅱🅲🅳ABCD Assessment Tool

Group	Exacerbations/yr	Symptoms (mMRC/CAT)	Initial Therapy
A	0–1 (no hosp)	Low (mMRC 0–1 / CAT <10)	Bronchodilator (short or long)
B	0–1 (no hosp)	High (mMRC ≥2 / CAT ≥10)	LABA or LAMA
E	≥2 or ≥1 hosp	Any	LABA + LAMA; consider ICS if eos ≥300

2023 GOLD update replaced C/D with single group E (exacerbation risk)

💊Inhaler Pharmacology Step-Up

Class	Duration	GCC Examples	Role
SABA — Short-acting beta-2 agonist	4–6 h	Salbutamol (Ventolin), Terbutaline	Reliever / rescue
SAMA — Short-acting muscarinic antagonist	6–8 h	Ipratropium (Atrovent)	Add to SABA in exacerbation
LABA — Long-acting beta-2 agonist	12–24 h	Salmeterol (Serevent), Formoterol, Indacaterol (Onbrez)	Maintenance — never without ICS in asthma
LAMA — Long-acting muscarinic antagonist	24 h	Tiotropium (Spiriva), Umeclidinium, Glycopyrronium	First-line COPD maintenance
ICS — Inhaled corticosteroid	24 h	Fluticasone (Flixotide), Budesonide (Pulmicort)	COPD: eos ≥300 or frequent exacerbations; Asthma: all patients
Triple therapy (LABA+LAMA+ICS)	24 h	Trelegy Ellipta (FF/UMEC/VI), Trimbow, Enerzair	Persistent exacerbations despite LABA+LAMA

ICS caution in COPD: Increased pneumonia risk with FEV1 <30%. Use only when eosinophil count ≥300 cells/μL or history of asthma-COPD overlap.

🫧Controlled Oxygen Therapy

Target SpO2 88–92% in COPD — hypercapnic respiratory failure risk. Higher oxygen removes hypoxic drive in CO2 retainers, worsens V/Q mismatch (Haldane effect), and causes hyperoxia-induced hypercapnia.

Delivery Devices

Venturi mask (preferred): Accurate FiO2 delivery — 24%, 28%, 35%, 40%, 60%
Nasal cannulae: Variable FiO2; each 1 L/min ≈ +4% FiO2 from 21% baseline
Simple face mask: FiO2 35–55%; imprecise — avoid in COPD exacerbation
Non-rebreathe mask: FiO2 60–90%; use only in severe hypoxaemia without CO2 retention

BTS Alert card: Patients with COPD should carry controlled oxygen alert card specifying target SpO2 88–92% for paramedics and emergency teams.

🌬️NIV in COPD — BiPAP

Initiation Criteria

pH < 7.35 AND PaCO2 > 6 kPa (type 2 respiratory failure)
Persisting despite maximum controlled O2 and bronchodilators (1–4 hours)
Patient able to protect airway; not immediately requiring intubation
No contraindication (undrained pneumothorax, facial fractures, vomiting)

Initial BiPAP Settings

Parameter	Starting Value	Range
IPAP (Inspiratory)	14–16 cmH2O	12–20 cmH2O
EPAP (Expiratory)	4–5 cmH2O	4–6 cmH2O
Backup rate	14–16 /min	12–20 /min
Inspiratory time	0.8–1.2 s	Titrate to comfort
O2 target SpO2	88–92%	Titrate FiO2

ABG repeat at 1–2 hours post-NIV initiation. pH improving >7.30 = good response. pH not improving or patient deteriorating = escalate to ICU for intubation.

🌿End-Stage COPD & Palliative Care

Indicators of End-Stage Disease

FEV1 <30% predicted (GOLD 4)
Multiple hospitalisations per year
MRC grade 5 breathlessness
Cor pulmonale / right heart failure
BMI <21 (nutritional failure)
Patient has declined or failed NIV/ventilation

Palliative Interventions

Opioids for dyspnoea: Low-dose oral morphine 2.5–5 mg 4-hourly — evidence-based, safe at low doses
Palliative oxygen: Only beneficial if SpO2 <88%; consider if subjective relief
Anxiolytics: Lorazepam 0.5–1 mg for acute dyspnoea episodes
EPAP fan therapy: Handheld fan to face reduces dyspnoea perception
Advance care planning: DNAR, resuscitation wishes, ceiling of care discussion
Pulmonary rehabilitation: Improves quality of life even in severe disease

Common COPD Exacerbation Triggers

Viral URTI (Rhinovirus, Influenza) Bacterial (H. influenzae, S. pneumoniae, M. catarrhalis) Air pollution / sandstorm Non-compliance with inhalers Temperature changes Aspiration PE (underdiagnosed)

😷NIV Indications

Indication	Mode	Evidence
COPD acute exacerbation (type 2 RF)	BiPAP	Strong — reduces intubation & mortality
Cardiogenic pulmonary oedema	CPAP	Strong — improves oxygenation, reduces work of breathing
Obesity hypoventilation syndrome	BiPAP	Strong — nocturnal then as needed
Post-extubation prophylaxis (high-risk)	BiPAP/CPAP	Moderate
Neuromuscular disease (e.g. MND)	BiPAP	Strong — improves survival in MND
Chest wall deformity (kyphoscoliosis)	BiPAP	Moderate
Immunocompromised (avoid intubation)	BiPAP/HFNO	Moderate

🚫NIV Contraindications & Failure

Absolute Contraindications

Respiratory arrest / apnoea
Unable to protect airway (reduced GCS, absent gag reflex)
Copious secretions / vomiting (aspiration risk)
Undrained pneumothorax
Facial trauma / surgery / burns
Bowel obstruction / recent upper GI surgery

NIV Failure Criteria — Escalate to Intubation

pH <7.25 or worsening acidosis despite NIV at 1–2 hours
Respiratory rate >35 or increasing despite NIV
SpO2 <85% with FiO2 >60%
Deteriorating consciousness or agitation
Haemodynamic instability (SBP <90 despite resuscitation)
Patient unable to tolerate mask / persistent large leak

NIV is a bridge, not destination. Failure to respond within 1–2 hours requires urgent senior review and ICU referral.

🩺NIV Mask Fitting & Nursing Management

Mask Types

Full face mask: Covers nose and mouth; first choice in acute setting; less leak; risk of claustrophobia
Nasal mask: Comfortable for home NIV; requires mouth closure; leak via mouth reduces efficacy
Total face mask: Covers entire face; good for claustrophobic patients; skin protection
Nasal pillows: Minimal contact; home NIV; less suitable for acute use

Leak Management

Acceptable leak <24 L/min (machine-reported)
Refit mask — harness should be snug but not tight (2 fingers under strap)
Chinstrap for nasal mask mouth leak
Consider mask size — measure nasion to chin
Check interface for cracks/damage
Document leak level each hour

Comfort & Complications

Claustrophobia: Hold mask before strapping, gradual pressure build-up, reassurance, short-acting anxiolytic if needed
Pressure sores: Inspect nasal bridge hourly — apply hydrocolloid/foam dressing prophylactically
Humidification: Heated humidifier reduces dryness and improves tolerance — essential for >4 hours use
Aerophagia: Gastric distension — semi-recumbent position, reduce IPAP if severe

NIV Monitoring Schedule

Time	Assessment	Action
Every 15 min (first hour)	RR, SpO2, HR, BP, consciousness, mask seal	Adjust settings, refit mask, reassure
1–2 hours	ABG — critical decision point	pH improving? Continue. pH worsening? Escalate
Every 2–4 hours	Clinical response, skin integrity, secretions	Suction breaks, skin care, meal breaks off NIV
4–6 hours	Consider weaning trial — brief mask removal	Monitor SpO2 off NIV

⚙️Invasive Ventilation Modes (Awareness)

Mode	Full Name	Key Feature
`VC`	Volume Control	Set tidal volume guaranteed; pressure varies
`PC`	Pressure Control	Set pressure; tidal volume varies
`PRVC`	Pressure Regulated Volume Control	Adaptive — pressure adjusts to achieve set volume
`SIMV+PS`	Synchronised Intermittent Mandatory Ventilation + Pressure Support	Set mandatory breaths + patient-triggered PS breaths; weaning mode
`PSV/ASB`	Pressure Support	Spontaneous breathing — augments patient effort; weaning

🫁ARDS — Berlin Definition & Lung Protective Ventilation

Berlin Definition (2012)

Category	PaO2/FiO2 (mmHg)	PaO2/FiO2 (kPa)
Mild ARDS	200–300	26.6–40 kPa
Moderate ARDS	100–200	13.3–26.6 kPa
Severe ARDS	<100	<13.3 kPa

PEEP ≥5 cmH2O required; onset within 1 week; bilateral infiltrates not explained by cardiac failure

Lung Protective Strategy (ARDSNet)

Tidal volume: 6 mL/kg Ideal Body Weight (IBW) — avoid volutrauma
Plateau pressure: <30 cmH2O — monitor with inspiratory hold
Driving pressure: <15 cmH2O (Plateau – PEEP)
Permissive hypercapnia: Accept PaCO2 up to 8–10 kPa if pH >7.20
PEEP: Optimise by PEEP/FiO2 table or transpulmonary pressure
Prone positioning: 16 hours/day in moderate-severe ARDS — reduces mortality

🫁Bronchiectasis — Diagnosis & Scoring

CT Diagnostic Criteria

Internal airway diameter > adjacent pulmonary artery (signet ring sign)
Airway visible within 1 cm of pleura (normally not visible)
Lack of tapering of bronchi towards periphery
Patterns: cylindrical (mild), varicose, cystic (severe)

FACED Score (Prognostic)

Parameter	Criteria	Points
FEV1	<50% predicted	2
Age	≥70 years	2
Chronic Pseudomonas colonisation	Yes	1
Extension (lobes involved)	≥3 lobes on CT	1
Dyspnoea (mMRC)	mMRC ≥2	1

Score 0–2: mild; 3–4: moderate; 5–7: severe. Higher scores predict 5-year mortality.

🦠Sputum Microbiology & Antibiotic Strategy

Organism	Treatment Approach
H. influenzae (most common)	Amoxicillin/clavulanate or doxycycline; 14 days
Pseudomonas aeruginosa	IV anti-pseudomonal (Pip-Tazo, Ceftazidime, Meropenem); oral ciprofloxacin in mild-moderate
MRSA	IV Vancomycin or Teicoplanin; oral Linezolid
NTM (M. avium complex)	Macrolide + rifampicin + ethambutol; 12–18 months
Aspergillus	ABPA — prednisolone + itraconazole

Long-Term Azithromycin

250 mg three times weekly or 500 mg three times weekly
Indications: ≥3 exacerbations/year or chronic Pseudomonas colonisation
Exclude NTM before starting (azithromycin monotherapy induces resistance)
Monitor: hearing (ototoxicity), ECG QTc (prolongation), LFTs
Annual review; stop if NTM isolated or QTc >500 ms

💨Airway Clearance Techniques (ACT)

ACBT — Active Cycle of Breathing

Breathing control (relaxed, tidal breathing)
Thoracic expansion exercises (3–4 deep breaths + inspiratory hold)
Forced expiration technique — 1–2 huffs (glottis open)
Return to breathing control

Gold standard; no equipment required; 20–30 minutes; twice daily minimum

PEP — Positive Expiratory Pressure

Breathe out through PEP mask/mouthpiece against resistance
Pressure 10–20 cmH2O (set by physiotherapist)
Splints open collateral airways — mobilises peripheral secretions
12–15 breaths, then huff or cough
Clean device daily

Oscillating PEP Devices

Acapella: Magnetic oscillation; can be used in any position; washable
Flutter: Steel ball oscillation; requires upright position
Aerobika: OPEP with manometer; good for severe disease

Nebulised Treatments for Airway Clearance

Hypertonic saline (6–7%): Hydrates mucus, improves mucociliary clearance. Give before ACT. Pre-medicate with bronchodilator to prevent bronchospasm. Check FEV1 first use
DNase (Dornase alfa/Pulmozyme): Cleaves extracellular DNA from neutrophils in mucus. CF patients — 2.5 mg nebulised once daily. Evidence mainly in CF; limited in non-CF bronchiectasis
0.9% saline: Basic adjunct for mucus hydration

Bronchiectasis Exacerbation Management: Increased sputum volume/purulence + ≥1 of: increased dyspnoea, haemoptysis, increased fatigue, fever >38°C. Treat with 14-day antibiotics guided by previous sputum culture. Intensify ACT frequency.

🧬Cystic Fibrosis in GCC

CFTR Modulators — Available in GCC

Drug	Brand	Mutation	Age
Elexacaftor/Tezacaftor/Ivacaftor	Kaftrio / Trikafta	F508del (het/hom) + minimal function	≥2 years
Ivacaftor alone	Kalydeco	G551D + 9 gating mutations	≥4 months
Lumacaftor/Ivacaftor	Orkambi	F508del homozygous	≥2 years

Kaftrio/Trikafta represents transformational therapy — reduces pulmonary exacerbations by 63%, improves FEV1 by 13–14 percentage points. Access varies across GCC countries — Saudi MOH formulary approval process.

CF Annual Review Components

Spirometry (FEV1, FVC, FEF25-75)
Sputum culture + sensitivity (including fungal)
Pseudomonas eradication protocol if new isolation
OGTT (CF-related diabetes — 20% by age 30)
DEXA bone density scan
Fat-soluble vitamins (A, D, E, K)
Liver function (cirrhosis risk)
Nutritional assessment + BMI
Psychological assessment
Fertility counselling (males: congenital absence vas deferens)

Pseudomonas Eradication Protocol

First isolation: nebulised colistin + oral ciprofloxacin × 3 months
Repeat sputum at 3 months
Failure: IV anti-pseudomonal course (2–3 weeks)
Established chronic colonisation: long-term nebulised antibiotics (tobramycin/colistin) alternating monthly

💧Pleural Effusion — Light's Criteria

Classification: Exudate vs Transudate

Light's Criteria	Exudate (any 1 met)	Transudate (none met)
Pleural:serum protein ratio	>0.5	≤0.5
Pleural:serum LDH ratio	>0.6	≤0.6
Pleural LDH absolute	>2/3 upper serum LDH limit	≤2/3

Transudate causes: Heart failure (most common), cirrhosis, hypoalbuminaemia, hypothyroidism, Meigs' syndrome

Exudate causes: Malignancy, parapneumonic, TB (very common in GCC), pulmonary embolism, rheumatoid arthritis, post-CABG

Nursing: Diagnostic Tap Assistance

Position patient sitting forward, arms on pillow (over bedtable)
Ensure USS marking confirmed; mark site with skin pen
Prepare sterile field, local anaesthetic, collection tubes (biochemistry/cytology/microbiology)
Monitor vital signs and SpO2 throughout
Apply pressure dressing post-procedure
Post-procedure CXR to exclude pneumothorax
Label and dispatch samples urgently; document volume drained

🩺Therapeutic Pleural Aspiration

Maximum 1.5 L per session — risk of re-expansion pulmonary oedema if more drained rapidly. Stop immediately if patient develops chest pain, dyspnoea, cough, or frothy sputum.

Procedure Nursing Responsibilities

Confirm informed consent documented
USS guidance — operator confirms current fluid location
Position: sitting upright leaning forward or lateral decubitus
Monitor: SpO2, HR, RR, BP every 5–10 minutes
Record volume drained; stop at 1.5 L or if symptoms develop
Post-procedure: sitting for 30 minutes, CXR, re-assess breathlessness improvement

Pleurodesis Nursing Care

Agents: Talc (most effective, slurry or poudrage) or Bleomycin
Pain management: Pre-medicate with analgesia (opioid ± NSAIDs) 30 min before; talc causes significant pleuritis
Positioning: Rotate patient every 15 minutes for 2 hours to distribute agent across pleural surfaces
Drainage: Clamp drain for 1–4 hours post-instillation per local protocol; then release to drain
Monitor temperature (fever common 4–12 hours), pain score, respiratory status

🔧Chest Drain Management

Drain Assessment

Finding	Meaning	Action
Swinging/oscillating	Drain patent, connected to pleural space	Normal — observe
Bubbling	Air leak from pleural space	Expected in pneumothorax — document
No swing, no bubble	Blocked drain or lung re-expanded	CXR; flush if blocked (by doctor/practitioner)
Continuous bubbling	Persistent air leak or loose connection	Check all connections; if persistent — respiratory/surgical review

Suction Indications

Persistent air leak with lung not expanding
Post-surgical (thoracotomy) — routine low-pressure suction
High output — –10 to –20 cmH2O (low-pressure)
Never apply high pressure (>–20 cmH2O) — risk of re-expansion oedema

Drain Nursing Safety

Underwater seal drain NEVER clamped unless during drain change or on specific instruction
Keep drain below chest level at all times — prevents backflow
Document drainage volume, colour, and air leak hourly
Patient mobilisation: carry drain bottle at thigh level; do not lift above waist
Dressing changes: sterile, check insertion site for surgical emphysema, infection
Pain management: analgesia before deep breathing exercises and coughing
NEVER irrigate chest drain without specific medical order

Accidental disconnection: Immediately ask patient to exhale and cough, cover with sterile petroleum gauze. Reconnect urgently. Inform medical team immediately.

💨Pneumothorax Management

Type	Definition	Size	Management
Primary (PSP)	No underlying lung disease; young, tall, male	<2 cm at hilum (BTS)	Discharge with outpatient follow-up
Primary		≥2 cm or breathless	Needle aspiration (16G/16Fr) → drain if fails
Secondary (SSP)	Underlying disease (COPD, fibrosis, CF)	<1 cm, not breathless	Admit for O2 + observation
Secondary		≥1 cm or breathless	Intercostal drain (small-bore 8–12Fr)
Tension	Any — haemodynamic compromise	Any	IMMEDIATE needle decompression (2nd ICS MCL) then drain

🔭Bronchoscopy Nursing

Pre-Procedure

Fast 4 hours (solids), 2 hours (clear fluids)
IV access; consent confirmed; remove dentures
Baseline SpO2, HR, BP documented
Topical anaesthesia: lidocaine spray to oropharynx + nebulised lidocaine
Conscious sedation: midazolam ± fentanyl; reversal agents available (flumazenil/naloxone)
Supplemental O2 via nasal cannulae during procedure

Post-Procedure Monitoring

SpO2 continuous for minimum 2 hours post-sedation
NPO until gag reflex returns (topical anaesthesia dissipates)
Monitor for haemoptysis (biopsy complication — most within 2 hours)
CXR at 2–4 hours if biopsy performed (exclude pneumothorax — 1–6%)
Observe for stridor, laryngospasm, or bronchospasm
Fever post-BAL — common, treat if persists >24 hours

Biopsy complications: Bleeding (manage by positional haemostasis — bleeding side down, cold saline lavage, adrenaline) and Pneumothorax (drain if symptomatic/large).

🏜️Environmental Respiratory Hazards

Sandstorms (Haboob)

PM2.5 and PM10 particles: penetrate deep airways, trigger bronchospasm
COPD/asthma exacerbations spike during and after sandstorm events (Saudi Arabia, UAE, Kuwait)
Nursing advice: Stay indoors; seal windows; use HEPA air purifiers; increase inhaler frequency pre-storm
N95/FFP2 mask outdoors — though poorly tolerated in heat
Monitor SpO2 at-risk patients during sandstorm advisory periods

Indoor Air Quality

Air conditioning systems: Poorly maintained AC units risk mould growth (Aspergillus, Cladosporium) and Legionella in cooling towers
Legionella risk: hospital HVAC, hotel cooling towers — regular maintenance essential
GCC construction boom: silica dust exposure in migrant workers — silicosis risk
Oil industry workers: hydrocarbon vapour, hydrogen sulphide exposure — occupational asthma, chemical pneumonitis

Industrial Respiratory Disease: Silicosis presenting as progressive fibrotic lung disease in construction workers from South Asia. TB reactivation risk with silicosis (silicotuberculosis). Screen with CXR and Mantoux/IGRA.

🚬Tobacco & Shisha in GCC

Shisha/Hookah — Clinical Significance

One shisha session ≈ 100–200 cigarettes in volume of smoke inhaled (WHO data). Long duration, charcoal CO production, and water cooling perception of harmlessness.

High carbon monoxide — COHb levels markedly elevated post-session
Second-hand shisha smoke in majlis (communal sitting areas) — children and non-smokers exposed
Social/cultural normalisation: nurse must address without stigma
COPD and lung cancer risk equivalent to or exceeding cigarette smoking
Electronic cigarettes (vaping) increasing, especially in younger GCC nationals

Smoking Cessation in GCC

5As approach: Ask, Advise, Assess, Assist, Arrange
NRT available: patches, gum, lozenges — culturally acceptable during non-fasting hours
Varenicline (Champix/Chantix): most effective; monitor mood/neuropsychiatric side effects
Arabic-language smoking cessation resources — use where available
Family-centred approach effective in GCC collectivist culture

😴Obstructive Sleep Apnoea in GCC

OSA prevalence significantly higher in GCC than global average — contributing factors: high obesity rates, retrognathia anatomical tendency in GCC Arab population, cultural normalisation of snoring.

Screening & Diagnosis

STOP-BANG score ≥3: High risk — refer for sleep study
Polysomnography (gold standard) or home sleep apnoea test
AHI >5/h = OSA; mild 5–14; moderate 15–29; severe ≥30

CPAP Nursing Support

CPAP adherence challenges: humidity, mask discomfort, noise, cultural barriers (partner in same room)
Auto-CPAP initiation: pressures 4–20 cmH2O — machine sets optimal
Heated humidification: reduces dryness, improves adherence (especially in AC environments)
Mask selection: full face vs nasal vs nasal pillow — patient preference key
Follow-up at 1 month: download compliance data; target ≥4 hours/night ≥70% nights
OSA driving regulations: MOH guidelines — patients advised not to drive until OSA controlled

🕌Ramadan & Inhaler Education

Islamic Ruling on Inhalers During Ramadan

Islamic scholars' consensus (majority opinion): Inhaled medications (MDI, DPI, nebulisers) are PERMITTED during fasting. Medication does not nourish — it reaches the lungs, not the stomach. Patients must not stop essential respiratory medications during Ramadan.

Practical Nursing Guidance

Reassure patients: preventer and reliever inhalers are permissible during fasting
Advise patients to consult their local imam if still concerned — majority permit inhalers
Adjust timing where possible: LABA/LAMA once-daily — take at Iftar or Suhoor
Nebuliser treatments: if required, schedule at non-fasting hours or as medically necessary
Increased dehydration risk during Ramadan in GCC heat — thickens secretions; increase hydration at Iftar
Provide Arabic-language inhaler education leaflets

Arabic Inhaler Education Key Points

MDI technique: shake, exhale, seal, activate, slow deep inhale over 3–5 seconds, hold 10 seconds
DPI (Turbuhaler/Ellipta): fast forceful inhalation — opposite to MDI
Spacer: essential for MDI especially in elderly and children; reduces oral deposition
Rinse mouth after ICS — oral candidiasis prevention
Written action plan in Arabic — rescue vs maintenance inhaler distinction clear

🦠MERS-CoV & Respiratory Infections

MERS-CoV (Middle East Respiratory Syndrome)

Coronavirus endemic in Arabian Peninsula — dromedary camel reservoir
Incubation: 2–14 days; respiratory illness, often severe — 35% case fatality rate
Clinical: Fever, cough, dyspnoea, bilateral pneumonia → ARDS, renal failure
Risk factors: Camel contact, camel milk consumption, healthcare worker exposure
Isolation: Airborne + droplet + contact precautions in negative pressure room
PPE: FFP3/N99 mask, gown, gloves, goggles — don/doff protocol strictly
No specific antiviral approved — supportive care, oxygen, NIV/intubation as required

🕋Hajj Mass Gathering Respiratory Risks

Scale: 2+ million pilgrims from 180+ countries — world's largest annual mass gathering
Respiratory TB: High-risk countries in pilgrims; close crowded conditions accelerate transmission. Masks recommended for symptomatic pilgrims
Meningococcal disease: ACWY vaccine mandatory — respiratory droplet risk in crowded Mina/Muzdalifa
Influenza: Year-round risk during Hajj — universal vaccine recommended. Oseltamivir prophylaxis for vulnerable pilgrims
COPD/asthma pilgrims: Heat, exertion, crowds, smoke from incense — pre-Hajj optimisation essential. Carry adequate inhaler supplies (pharmacies in Makkah/Madinah limited)
Hyperthermia & dehydration: Worsens respiratory disease — ensure hydration, avoid peak sun hours
Nurse role: Pre-Hajj vaccination and medication review clinic; advise on inhaler transport and customs declaration